LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

Search

ResMed Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

252 0.44

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

249.71

Max

252.76

Pagrindiniai rodikliai

By Trading Economics

Pajamos

44M

393M

Pardavimai

87M

1.4B

P/E

Sektoriaus vid.

25.005

110.024

Dividendų pajamingumas

0.92

Pelno marža

27.593

Darbuotojai

10,600

EBITDA

63M

566M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+15.28% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.92%

2.26%

Kitas uždarbis

2026-04-22

Kitas dividendų mokėjimo data

2026-03-19

Kita Ex Dividend data

2026-05-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-426M

37B

Ankstesnė atidarymo kaina

251.56

Ankstesnė uždarymo kaina

252

Naujienos nuotaikos

By Acuity

17%

83%

23 / 351 reitingas Healthcare

ResMed Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-24 23:07; UTC

Uždarbis

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026-02-24 23:01; UTC

Uždarbis

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026-02-24 22:59; UTC

Uždarbis

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

2026-02-24 22:42; UTC

Uždarbis

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

2026-02-24 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

2026-02-24 23:46; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

2026-02-24 23:36; UTC

Rinkos pokalbiai

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

2026-02-24 23:30; UTC

Rinkos pokalbiai

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

2026-02-24 23:20; UTC

Rinkos pokalbiai

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

2026-02-24 23:20; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-24 23:16; UTC

Uždarbis

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

2026-02-24 23:13; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

2026-02-24 23:12; UTC

Uždarbis

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

2026-02-24 23:10; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

2026-02-24 23:10; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

2026-02-24 23:08; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

2026-02-24 23:07; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

2026-02-24 22:52; UTC

Uždarbis

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026-02-24 22:46; UTC

Uždarbis

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026-02-24 22:31; UTC

Įsigijimai, susijungimai, perėmimai

Warner Receives New Bid From Paramount -- 3rd Update

2026-02-24 22:29; UTC

Uždarbis

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

2026-02-24 22:28; UTC

Uždarbis

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

2026-02-24 22:27; UTC

Uždarbis

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

2026-02-24 22:27; UTC

Uždarbis

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

2026-02-24 22:25; UTC

Uždarbis

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

2026-02-24 22:24; UTC

Uždarbis

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

2026-02-24 22:23; UTC

Uždarbis

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

2026-02-24 22:22; UTC

Uždarbis

Woolworths Interim Dividend 45 Australian Cents/Share

2026-02-24 22:22; UTC

Uždarbis

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

2026-02-24 22:21; UTC

Uždarbis

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Akcijų palyginimas

Kainos pokytis

ResMed Inc Prognozė

Kainos tikslas

By TipRanks

15.28% į viršų

12 mėnesių prognozė

Vidutinis 300.64 USD  15.28%

Aukščiausias 345 USD

Žemiausias 265 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines ResMed Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

13 ratings

8

Pirkti

5

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

23 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę ResMed Inc

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
help-icon Live chat